US companies hopeful on overseas earnings tax amnesty
This article was originally published in Clinica
US device companies with significant overseas manufacturing facilities are lobbying for a tax amnesty provision that would let them bring their earnings home during a tax window of one year at a markedly reduced tax rate. Customarily, these earnings are reinvested in the country where they have been earned, as to bring them back to the US would incur a significant tax charge.
You may also be interested in...
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.